CN Patent

CN119654319A — 一种cdk抑制剂及其磷酸盐的多晶型

Assigned to Qilu Pharmaceutical Co Ltd · Expires 2025-03-18 · 1y expired

What this patent protects

本申请提供了一种式(A)化合物(N‑(1‑((4‑((3S，5S)‑3，5‑二甲基哌嗪‑1‑基)苯基)磺酰基)哌啶‑4‑基)‑4‑((S)‑四氢呋喃‑3‑基)氧基)‑5‑(三氟甲基)嘧啶‑2‑胺)的多晶型，以及式(A)化合物磷酸盐的多晶型，本申请提供的晶型具有较好的化学稳定性、物理稳定性以及较低的吸湿性，受温度、湿度和光照影响较小，便于储存及制剂开发。

USPTO Abstract

本申请提供了一种式(A)化合物(N‑(1‑((4‑((3S，5S)‑3，5‑二甲基哌嗪‑1‑基)苯基)磺酰基)哌啶‑4‑基)‑4‑((S)‑四氢呋喃‑3‑基)氧基)‑5‑(三氟甲基)嘧啶‑2‑胺)的多晶型，以及式(A)化合物磷酸盐的多晶型，本申请提供的晶型具有较好的化学稳定性、物理稳定性以及较低的吸湿性，受温度、湿度和光照影响较小，便于储存及制剂开发。

Drugs covered by this patent

Patent Metadata

Patent number
CN119654319A
Jurisdiction
CN
Classification
—
Expires
2025-03-18
Drug substance claim
No
Drug product claim
No
Assignee
Qilu Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.